Analysis: Physicians act as gatekeepers for new diagnostic tools

Frost & Sullivan reports that the number of diagnostic tests for cancer is growing at a rapid pace, but that physicians act as gatekeepers in the system, essentially preventing patients access to diagnostic tools that could save their lives. "Closing this gap is critical and companies are already striving to form partnerships involving diverse groups such as researchers, treatment professionals, policymakers at all levels, consumers as well as the public and private health sectors," says research analyst Raghavendra Chitta.

- read this press release for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.